DuPont de Nemours, Inc.

DuPont de Nemours, Inc. operates as a leading provider of advanced solutions, strategically positioned across the healthcare, water, construction, and industrial markets. The company's core business model revolves around leveraging innovation, specialized manufacturing capabilities, and established brands to address critical global challenges such as an aging population, water scarcity, and the demand for high-performance materials. Following a significant realignment in the fourth quarter of 2025, DuPont now reports through two primary revenue-generating segments: Healthcare & Water Technologies and Diversified Industrials. The company aims to enhance its competitive standing through continuous product innovation, technological advancements, sustainable practices, and robust customer support, underpinned by a global manufacturing footprint and local service capabilities.

The Healthcare & Water Technologies segment is a global leader in delivering innovative high-performance products, components, and solutions. Its Healthcare Technologies business focuses on specialized materials, product design, prototyping, and manufacturing services for medical device and biopharma markets, offering products like TYVEK® medical packaging and garments, and TYCHEM® protective suits, where technological advancement and quality assurance are paramount. The Water Technologies business within this segment provides advanced water filtration and separation solutions, including AMBERLITE™ ion exchange resins, FILMTEC™ reverse osmosis and nanofiltration elements, and INGE™ and ITEGRATEC™ ultrafiltration modules, primarily serving industrial wastewater, energy, municipal drinking water, desalination, and life sciences sectors. This segment's offerings are critical for efficient water purification and treatment, addressing growing global demand.

The Diversified Industrials segment provides engineered products and integrated solutions designed to enhance safety, performance, durability, and operational efficiency across various construction and industrial end markets. Its Building Technologies business offers solutions for non-residential, residential, and repair-and-remodel construction markets, including TYVEK® house wrap, STYROFOAM™ insulation, and CORIAN® solid surface, all aimed at supporting energy efficiency, durability, and comfort throughout a structure's lifespan. The Industrial Technologies business specializes in precision-engineered components, systems, and process solutions for critical OEM and operational applications in sectors such as aerospace, automotive, electric vehicles, printing, and packaging. Key brands like Vespel® shapes and parts, MOLYKOTE® specialty lubricants, BETAFORCE™ and BETASEAL™ structural adhesives, and Cyrel® flexographic printing plates contribute to light-weighting vehicles, improving safety, and enhancing product performance in demanding environments.

For the fiscal year ended December 31, 2025, DuPont reported total net sales of $6,849 million, representing a 2 percent increase from $6,719 million in 2024, which itself was up 2 percent from $6,614 million in 2023. The 2025 revenue growth was primarily driven by a 3 percent increase in volume, partially offset by a 1 percent decrease due to local price and product mix. Gross profit for 2025 stood at $2,363 million, yielding a gross margin of 34.5 percent, an expansion from 33.0 percent in 2024 and 32.8 percent in 2023. Operating income from continuing operations before income taxes reached $200 million in 2025, a significant improvement from $117 million in 2024 and a loss of $279 million in 2023, translating to an operating margin of 2.9 percent in 2025, up from 1.7 percent in 2024 and a negative 4.2 percent in 2023. Net income from continuing operations, net of tax, was $98 million in 2025, recovering from a net loss of $96 million in 2024 and $62 million in 2023. Basic and diluted earnings per share from continuing operations were $0.21 in 2025, compared to a loss of $0.23 in 2024 and $0.15 in 2023. The company reported a net loss available for DuPont common stockholders of $779 million in 2025, a notable shift from net income of $703 million in 2024 and $423 million in 2023, primarily due to a substantial loss from discontinued operations.

Free cash flow from continuing operations, calculated as cash provided by operating activities less capital expenditures, was $227 million in 2025, a decrease from $480 million in 2024 and $543 million in 2023. This decline in 2025 was primarily attributed to cash paid to settle interest rate swaps, fees related to debt transactions, and cash used by working capital. As of December 31, 2025, DuPont held $715 million in cash and cash equivalents, a decrease from $1,792 million at the end of 2024. Total debt significantly reduced to $3,194 million in 2025 from $7,171 million in 2024, resulting in a net debt position of $2,479 million in 2025, down from $5,379 million in 2024. The Healthcare & Water Technologies segment saw net sales increase by 9 percent in 2025 to $3,233 million, driven by a 7 percent volume increase and 1 percent from portfolio actions, while its Operating EBITDA grew 15 percent to $972 million. Conversely, the Diversified Industrials segment experienced a 3 percent decline in net sales to $3,616 million in 2025, due to 1 percent declines in volume, local price and product mix, and portfolio actions, leading to a 5 percent decrease in Operating EBITDA to $800 million.

Significant operational developments in 2025 included the completion of the Electronics Separation on November 1, 2025, which spun off Qnity Electronics, Inc. into an independent public company, with Qnity providing a cash distribution of approximately $4.1 billion to DuPont. This separation led to the classification of the Electronics Business as discontinued operations. Additionally, DuPont entered into a definitive agreement on August 29, 2025, to sell its Aramids business for gross consideration of $1.8 billion, comprising approximately $1.2 billion in pre-tax cash, a $300 million note receivable, and a $325 million non-controlling common equity interest in the acquiring entity, Arclin, with the transaction expected to close around the end of the first quarter 2026. The company also completed the acquisition of Sinochem (Ningbo) RO Memtech Co., Ltd. for $56 million on October 10, 2025, enhancing its Water Technologies business. In 2024, DuPont acquired Donatelle Plastics, LLC for $365 million, strengthening its Healthcare Technologies offerings. These portfolio actions, alongside the 2023 acquisition of Spectrum Plastics Group for $1,781 million and the Delrin® business divestiture for $1.28 billion cash proceeds, a $350 million note receivable, and a 19.9 percent noncontrolling equity interest in Derby Group Holdings LLC, underscore DuPont's ongoing transformation. Restructuring efforts continued with the approval of a Transformational Separation-Related Restructuring Program in March 2025, incurring $69 million in pre-tax charges, alongside ongoing 2023-2024 and 2022 restructuring programs. A goodwill impairment charge of $768 million related to the Aramids Business was recognized in 2025 within discontinued operations, following a $668 million charge for the Protection reporting unit in 2023. The company also announced a new $2 billion share repurchase authorization in November 2025, initiating a $500 million accelerated share repurchase transaction in the fourth quarter of 2025, which resulted in the initial delivery of 10.2 million shares at $39.15 per share, with a total of 12.2 million shares repurchased at an average price of $40.89 per share by January 2026. Debt management included the repayment of approximately $4.0 billion aggregate principal amount of senior notes following the Electronics Separation, alongside debt exchange, consent solicitation, and tender offer activities. Furthermore, DuPont recorded a pre-tax charge of $186 million in 2025 related to the proposed Judicial Consent Order with the State of New Jersey concerning PFAS matters, building on a $408 million contribution to the Water District Settlement Fund in 2024.

For the full year 2026, DuPont anticipates continued growth within its Healthcare business, driven by broad-based strength in medical packaging applications and medical devices. The Water Technologies business is also expected to experience sustained growth, primarily fueled by demand for reverse osmosis and ion exchange technologies within both industrial and municipal water markets. In contrast, the Building Technologies segment is projected to remain approximately flat year-over-year, following a period of market declines, as the company expects stabilization within the U.S. construction markets. The Industrial Technologies business is forecast to achieve low-single digit growth, supported by strength in aerospace markets and a demand recovery across the remaining industrial-based product lines served by DuPont.

DuPont's strategic growth initiatives for the upcoming period are centered on continued portfolio optimization, leveraging advanced technologies, and enhancing operational efficiencies. The company plans to maintain its focus on innovation, with research and development expense remaining consistent at approximately 3 percent of net sales. Capital expenditures for 2026 are projected to be around $320 million, reflecting ongoing investments in its operational assets to support anticipated demand and strategic priorities. In terms of capital allocation, the company has a remaining authorization of $1.5 billion under its $2 billion share repurchase program approved in November 2025, indicating a continued commitment to returning value to shareholders. DuPont also expects to continue its policy of paying quarterly dividends, subject to Board approval.

The company has flagged several key structural headwinds and execution risks that could impact its growth plan. These include the ongoing macroeconomic environment, which can influence demand across its diverse end markets, as well as potential supply chain disruptions that could affect raw material availability and costs. The ability to effectively integrate acquired businesses and successfully execute planned divestitures, such as the Aramids business sale, remains critical. Furthermore, the company faces risks associated with the highly competitive landscape, evolving regulatory requirements, and the need to attract and retain talented employees. Management has also committed to a new restructuring plan, anticipating pre-tax costs of approximately $100 million to $150 million, starting in the first quarter of 2026 and continuing through 2028, aimed at further reducing costs and streamlining operations to align with its strategic priorities.

DuPont faces a multifaceted risk landscape encompassing material macroeconomic, competitive, regulatory, geopolitical, and operational challenges. Macroeconomic risks include broad changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets, pandemics, and natural disasters, with inflationary pressures potentially increasing costs and impacting financial results. Competitively, the company is exposed to shifts in product innovation, technological advancements, pricing strategies, customer services, and the regulatory environment, with a failure to adapt potentially leading to reduced competitiveness or loss of market share. Regulatory risks are significant, stemming from extensive environmental laws and regulations concerning pollution, greenhouse gas emissions, hazardous substances, and PFAS, alongside increasing sustainability reporting and supply chain due diligence requirements, with compliance costs and potential sanctions posing material impacts. Geopolitical tensions, particularly trade disputes between the U.S. and China, export controls, and investigations by foreign governments such as the SAMR investigation into the Tyvek® business, which represented approximately 1 percent of DuPont’s 2025 consolidated net sales, could adversely affect operations and reduce product competitiveness. Operationally, the company is vulnerable to supply chain and operational disruptions, plant or power outages, labor shortages, and cybersecurity threats, including phishing, hacking, and industrial espionage, which could lead to misuse of assets, loss of intellectual property, legal claims, and reputational damage. The enforcement of intellectual property rights and defense against claims by others also present ongoing legal and financial risks. Furthermore, the company's financial results are susceptible to potential impairments of goodwill and other intangible assets, particularly given the significant judgments involved in fair value estimates, and the failure to effectively manage acquisitions, divestitures, and alliances could impede the realization of anticipated benefits. The company also faces continuing contingent tax-related liabilities from past separations and divestitures, including the Qnity, M&M, N&B, and DWDP transactions, with potential significant tax liabilities if these transactions fail to qualify for non-recognition treatment for U.S. federal income tax purposes. The cost-sharing arrangement under the PFAS MOU, including the proposed Judicial Consent Order with the State of New Jersey, which resulted in a $186 million charge in 2025, and the $408 million contribution to the Water District Settlement Fund in 2024, represents ongoing financial exposure, with considerable uncertainty regarding future remediation costs that could range up to $271 million above current accruals. Changes in credit ratings could also increase borrowing costs and restrict access to debt capital markets, while the ability to attract and retain talented personnel remains crucial for achieving strategic goals.

Management's message to shareholders conveys a clear and consistent tone of strategic transformation and disciplined execution, emphasizing the company's evolution into a focused advanced solutions provider. The leadership team is committed to optimizing its portfolio, driving growth in core businesses, and enhancing shareholder value through a balanced financial policy. They highlight the significant progress made through strategic divestitures, such as the Electronics Separation and the planned Aramids Divestiture, which are reshaping DuPont's operational footprint and financial structure.

For the upcoming period, management has provided specific forward-looking statements and guidance ranges, projecting continued growth in Healthcare and Water Technologies, with anticipated low-single digit growth in Industrial Technologies, while Building Technologies is expected to stabilize. Capital expenditures are planned at approximately $320 million for 2026, and long-term employee benefit expense is expected to increase by about $12 million. A new restructuring plan, with estimated pre-tax costs of $100 million to $150 million from the first quarter of 2026 through 2028, underscores their commitment to operational efficiency.

The two or three strategic priorities emphasized by management for the period ahead include first, the continued optimization of DuPont's portfolio through strategic divestitures and targeted acquisitions to sharpen its focus on high-growth, high-margin advanced solutions. Second, they are prioritizing organic growth within the Healthcare & Water Technologies and specific Industrial Technologies segments, driven by innovation and market demand. Third, management is dedicated to maintaining a strong financial position, evidenced by the $2 billion share buyback authorization and the expectation to continue quarterly dividends, all while upholding an investment-grade credit rating.